Further, should PARP inhibitors be combined with other DNA-damaging agents such as chemo or radiotherapy, a patient’s HRD status may become less relevant, as early evidence suggests that such approaches may have efficacy in multiple TP53 mutated but HR-intact tumor types70. The gene discussed is TP53; the disease is neoplasm.